Global health agency Unitaid has awarded French Medincell Corp (Jacou) an extension grant of up to US$ 6 million over three years to fund thesatety testing of its malaria vaccine mdc-STM.
Genmab announced today that it will acquire privately held biotech company ProfoundBio for $1.8bn in cash. The deal is designed to help the Danish pharmaceutical company deepen its cancer pipeline with next-generation antibody-drug conjugate therapies where the company has already an inlicensing deal with former Synaffix´s ADC technology platform (which was acquired mid of 2023 by Lonza).
TME Pharma (France/Germany) announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for NOX-A12 (olaptesed pegol), TME Pharma’s CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer glioblastoma.
Forbion, the European life sciences venture capital firm from The Netherlands, announced its participation in oversubscribed Series B financing in Capstan Therapeutics Inc. and Engrail Therapeutics. Both companies are located in San Diego, USA.
With a new law, the German government wants to increase the number of clinical trials conducted in Germany and make the country number one in Europe again.
A bacterium of the gut microbiome seems to spark an autoimmune disease in the kidneys by leaking antigens that trigger the immune system.
Cultivated meat producer Innocent Meat GmbH has cashed in €3m in funding from Venture Capital Fonds MV and an anonymous business angel.
Spanish Ferrer Internacional, SA has aquired the ex-US rights to VRG50635 from Verge Genomics Inc to commercialise the oral Phase I experimental ALS treatment.
Novo Nordisk is set to acquire German miRNA blocker specialist Cardior Pharmaceuticals GmbH for up to €1.025bn including milestone payments.
Researchers at NDM Pharma A/S and Aarhus University have demonstrated that their oral CIC-1 blocker NMD670 restores crosstalk between neurons and muscles in Myasthenia gravis.